David A. Siegel Savara Inc Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Savara Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 499,115 shares of SVRA stock, worth $2.01 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
499,115
Previous 36,215
1278.2%
Holding current value
$2.01 Million
Previous $170,000
1361.76%
% of portfolio
0.01%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding SVRA
# of Institutions
123Shares Held
121MCall Options Held
123KPut Options Held
14.7K-
Nea Management Company, LLC Timonium, MD24.5MShares$98.6 Million8.55% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA14.6MShares$58.7 Million10.96% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA10MShares$40.3 Million5.24% of portfolio
-
Jennison Associates LLC8.84MShares$35.6 Million0.03% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.29MShares$33.4 Million0.08% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $460M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.